NovAliX Partners with Bruker to Enhance Drug Discovery

• NovAliX has secured a partnership with Bruker Corporation, which includes a minority investment.

• The collaboration aims to enhance drug discovery through advanced biophysical and structural biology methods.

NovAliX, a French preclinical Contract Research Organisation (CRO), has formed a new partnership with Massachusetts-based Bruker Corporation. Announced on 7 August, Bruker has made a minority investment in NovAliX, which will bolster the CRO’s capabilities in biophysics and drug discovery.

The collaboration will focus on developing advanced methods in structural biology and biophysics, including characterising molecular dynamics and drug candidate interactions. This partnership aims to identify new drug targets and predict potential failures earlier in the discovery process.

“This partnership with Bruker will fortify our leadership in biophysics and drug discovery,” said NovAliX co-founder and President Stephan Jenn. The goal is to leverage Bruker’s analytical technologies to offer cutting-edge biophysical methods to clients.

Earlier this year, NovAliX also partnered with the Max Planck Institute for Multidisciplinary Sciences to advance basic research into therapeutic applications.